| Literature DB >> 28959646 |
Joanna A Ruszkiewicz1, Adi Pinkas1, Beatriz Ferrer1, Tanara V Peres1, Aristides Tsatsakis2, Michael Aschner1.
Abstract
Sunscreen application is the main strategy used to prevent the maladies inflicted by ultraviolet (UV) radiation. Despite the continuously increasing frequency of sunscreen use worldwide, the prevalence of certain sun exposure-related pathologies, mainly malignant melanoma, is also on the rise. In the past century, a variety of protective agents against UV exposure have been developed. Physical filters scatter and reflect UV rays and chemical filters absorb those rays. Alongside the evidence for increasing levels of these agents in the environment, which leads to indirect exposure of wildlife and humans, recent studies suggest a toxicological nature for some of these agents. Reviews on the role of these agents in developmental and endocrine impairments (both pathology and related mechanisms) are based on both animal and human studies, yet information regarding the potential neurotoxicity of these agents is scant. In this review, data regarding the neurotoxicity of several organic filters: octyl methoxycinnamate, benzophenone-3 and -4, 4-methylbenzylidene camphor, 3-benzylidene camphor and octocrylene, and two allowed inorganic filters: zinc oxide and titanium dioxide, is presented and discussed. Taken together, this review advocates revisiting the current safety and regulation of specific sunscreens and investing in alternative UV protection technologies.Entities:
Keywords: 4-Methylbenzylidene camphor; Benzophenone-3; Neurotoxicity; Octocrylene; Octyl methoxycinnamate; Sunscreen; Titanium dioxide; Zinc oxide
Year: 2017 PMID: 28959646 PMCID: PMC5615097 DOI: 10.1016/j.toxrep.2017.05.006
Source DB: PubMed Journal: Toxicol Rep ISSN: 2214-7500
Organic UV filters.
| International nomenclature of cosmetic ingredients (INCI) | ||
|---|---|---|
| 4-methylbenzylidene camphor* | Enzacamene | |
| Homosalate | Homosalate | |
| Isoamyl- | Amiloxate | |
| Octyl dimethyl PABA | Padimate O | OD-PABA |
| Octyl methoxycinnamate | Octinoxate | 2-ethylhexyl 4-methoxy cinnamate |
| Octyl salicylate | Octisalate | 2-ethylhexyl salicylate |
| p-aminobenzoic acid | p-aminobenzoic acid | 4-aminobenzoic acid, PABA |
| Triethanolamine | Trolamine salicylate | |
| Disodium phenyl dibenzimidazole tetrasulfonate | Bisdisulizole disodium | |
| Butyl methoxydibenzoylmethane | Avobenzone | |
| Menthyl anthranilate | Meradimate | |
| Terephthalylidene dicamphor sulfonic acid | Ecamsule | Mexoryl SX |
| Benzophenone-3 | Oxybenzone | 2-hydroxy-4-methoxybenzophenone |
| Benzophenone-4 | Sulisobenzone | |
| Benzophenone-8 | Dioxybenzone | |
| 3-Benzylidene camphor | Mexoryl SD | |
| Bis-ethylhexyloxyphenol methoxyphenyl triazine | Bemotrizinol | Tinosorb S |
| Cinoxate | Cinoxate | |
| Drometrizole trisiloxane | Mexoryl XL | |
| Methylene bis-benzotriazolyl Tetramethylbutylphenol | Bisoctrizole | Tinosorb M |
| Octocrylene | Octocrylene | 2-ethylhexyl 2-cyano-3,3-diphenylacrylate |
| Phenylbenzimidazole sulfonic acid | Ensulizole | |
Not approved by the Food and Drug Administration, used in other parts of the world.
Neurotoxic effects of organic UV filters.
| Compound | ||||
|---|---|---|---|---|
| Wistar rats | Oral (gavage) administration during gestation and lactation | Decreased motor activity in female offspring, increased spatial learning in male offspring. | ||
| Sprague-Dawley rats, female | Oral (gavage) administration for | Non-estrogenic interference within the rodent HPT axis; no changes in pre-proTRH mRNA in mediobasal-hypothalamus. | ||
| Wistar rats | Decreased hypothalamic release of GnRH. Increased GABA release and decreased Glu production in males. | |||
| Wistar rats | Decreased hypothalamic release of LHRH. Increased GABA release in males, decreased Asp and Glu levels in females. | |||
| SH-SY5Y neuroblastoma cell line | 72 h | Decreased cell viability and increased caspase-3 activity. | ||
| Waterborne | Anti-androgenic activity: decreased expression of | |||
| Sprague-Dawley rats | Dermal application | No changes in behavioral tests (locomotor and motor coordination). | ||
| Rat primary cortical astrocytes and neurons | 1–7 days | Decreased cell viability of neurons but not of astrocytes. | ||
| SH-SY5Y neuroblastoma cell line | 72 h | Decreased cell viability and increased caspase-3 activity. | ||
| Waterborne | Upregulated estrogenic-related genes | |||
| Long Evans rats | Oral (in diet) administration during mating, pregnancy, lactation, until adulthood of offspring | Impaired female proceptive and receptive sexual behavior. Altered expression of oestrogen- related gens in a sex- and region −dependent manner. | ||
| Wistar rats | Subcutaneous administration during pregnancy | Altered hypothalamic release of Glu and Asp in male offspring. Inhibited testicular axis in male offspring during the pre-pubertal stage and stimulated during peri-pubertal stage. | ||
| Embryos exposed in medium | Inhibited AChE activity, impaired early muscular and neuronal development. | |||
| Neuro-2a mouse neuroblastoma cell line | 45 min | Inhibited AChE activity. | ||
| SH-SY5Y neuroblastoma cell line | 72 h | Decreased cell viability and increased caspase-3 activity. | ||
| Long Evans rats | Oral (in food) administration during mating, pregnancy, lactation, until adulthood of offspring | Impaired proceptive and receptive sexual behavior and disturbed estrous cycles of female offspring. Altered expression of oestrogen- related gens in a sex- and region-dependent manner. | ||
| Waterborne | Impaired expression of genes related with development and metabolism in the brain. |
Abbreviations: AChE: acetylcholine esterase; ar: androgen receptor; Asp: aspartate; cyp19b: cytochrome P450 aromatase b; esr1: estrogen receptor; GABA: gamma amino butyric acid; Glu: glutamate; GnRH: gonadotrophin-releasing hormone; HPT: hypothalamo-pituitary-thyroid; pre-proTRH: pre-pro-thyrotrophin-releasing hormone; vtg1, vitellogin 1; vtg3: vitellogin 3.
Neurotoxic effects of ZnO NPs.
| Compound | ||||
|---|---|---|---|---|
| Wistar rats | Intraperitoneal injection biweekly, 8 weeks | Attenuated spatial cognition capability, enhanced long-term potentiation. | ||
| Wistar rats | Intravenous injection single dose | Increased brain Zn concentrations; no changes in neurotransmitter levels, locomotor activity, exploratory behavior or spatial working memory. | ||
| Wistar rats, male | Intraperitoneal injection, 10 days | Decreased iron and calcium, but not Zn, sodium and potassium levels in rat brain homogenates; unchanged emotional behavior. | ||
| Wistar rats, male | Oral (gavage) | Elevated TNF-α, IL-1β, IL-6, CRP, MDA, decreased GSH and SOD levels, CAT, and GPx activity. | ||
| Sprague-Dawley rats | Oral | Increased Zn levels in the brain of male rats. | ||
| C57BL/6J mice, male | Intraperitoneal injection 3 times per week, 4 weeks | Impaired learning and memory abilities, suppression of cAMP/CREB signaling pathway. | ||
| Swiss albino mice, male | Intraperitoneal injection every other day, 8 times | Improved behavioral and cognitive impairment in mice with depressive-like behaviors. | ||
| Swiss albino mice, male | Oral | Elevated ROS levels, altered antioxidant system, increased DA and NE levels, presence of ZnO NPs in neurons. | ||
| ICR mice, pregnant female | Subcutaneous at GD 5, 8, 11, 14, 17 | Changed DA, 5-HT and their metabolites levels in a 6-week old offspring. | ||
| Waterborne | Changed CAT, SOD, GPx activity, GSH levels and lipid peroxidation. | |||
| Waterborne | Increased protein oxidative damage, decreased AChE activity. | |||
| Oral (food) | Decreased brain weight and increased brain AChE and GST activity. | |||
| Isolated rat neurons | 1 mg/ml | Increased the opening number of sodium channels, delayed rectifier potassium channels, enhanced excitability of neurons. | ||
| Rat primary neurons | 24 h | Concntration-dependent cytotoxicity, disrupted cell membranes, DNA damage. | ||
| Mouse neural stem cells | 24 h | Concentration-dependent decrease in cell viability; apoptosis, necrosis, release of zinc ions. | ||
| RCS96 rat Schwann cells | 6–48 h | Concentration- and time-dependent decrease in cell viability; apoptosis and necrosis, G2/M phase cell cycle arrest, release of Zn ions. | ||
| Human olfactory | 2–24 h | Decreased cell viability, activation of numerous pathways associated with stress, inflammation and apoptosis. | ||
| RCG-5 rat retinal ganglion cells | 4–72 h | Concentration- and time-dependent decrease in cell proliferation; cell cycle arrest, ROS generation, increased caspase-12, decreased bcl-2 and caspase-9. | ||
| RCG-5 rat retinal ganglion cells | 6–72 h | Decreased mitochondrial membrane potential, increased ROS production, increased caspase-12. | ||
| RCG-5 rat retinal ganglion cells | 4–72 h | Decreased expression and activity of the plasma membrane calcium ATPase, disrupted intracellular calcium homeostasis, increased ROS production. | ||
| PC12 rat pheochromocytoma and SH-SY5Y human neuroblastoma | 24 h | Decreased cell viability, mitochondrial impairment, internalization of ZnO NPs in membrane-bound vesicles. | ||
| SH-SY5Y human neuroblastoma | 6, 12, 24 h | Concentration- and time-dependent decrease in cell viability; apoptosis via the PI3 K/Akt/caspase-3/7 pathway and necrosis by LOX-mediated ROS production. | ||
| SH-SY5Y human neuroblastoma | 3–48 h | Concentration- and time-dependent decrease of cell viability, apoptosis and cell cycle alterations, genotoxicity: micronuclei, H2AX phosphorylation, DNA damage. | ||
| U87 human brain tumor | 24 h | Concentration-dependent cytotoxicity e.g. increased formation of micronuclei. | ||
| Rat primary astrocytes | 6, 12, 24 h | Reduced cell viability, increased LDH release, stimulated ROS generation, caspase-3 activation, decreased MMP, phosphorylated JNK, ERK, p38 MAPK. | ||
| C6 glia cells | 3, 6, 24 h | Time- and concentration-dependent cytotoxicity, apoptosis and increased ROS production. | ||
| A172, U87, LNZ308, LN18, LN229 glioma cell lines and normal human astrocytes | 24 h | Cytotoxicity and ROS generation in glioma lines, but not in normal human astrocytes. | ||
| N9 mouse microglial cell line | 5–60 min; 1–24 h | Increased intracellular calcium and ROS levels, decreased intracellular ATP level, upregulated apoptosis markers. | ||
| BV-2 mice microglia cell line | 2–24 h | Increased cytotoxicity; activated PINK1/parkin-mediated mitophagy. |
Abbreviations: 5-HT: 5-hydroxytriptamine; Akt: protein kinase B; cAMP: cyclic adenosine monophosphate; CAT: catalase; CREB: cAMP response element binding protein; CRP: c-reactive protein; DA: dopamine; ERK: extracellular signal-related kinase; GSH: glutathione; GPx: glutathione peroxidase; GST: glutathione-S-transferase; H2AX: H2A histone family member X; IL-1β: interleukin-1β; IL-6: interleukin-6; JNK: c-Jun N-terminal kinase; LDH: lactate dehydrogenase; LOX: lipoxygenase; MDA: malondialdehyde; MMP: mitochondrial membrane potential; NE: norepinephrine; NPs: nanoparticles; p38 MAPK: p38 mitogen-activated protein kinase; PINK1: PTEN-induced putative kinase 1; PI3 K: phosphoinositide 3-kinase; ROS: reactive oxygen species; SOD: superoxide dismutase; TNF-α: tumor necrosis factor α; Zn: zinc; ZnO: zinc oxide.
Neurotoxic effects of TiO2 NPs.
| Compound | ||||
|---|---|---|---|---|
| Mice | Intratracheal instillations once per week for 4 weeks | Inflammatory cell aggregation and neuron necrosis. Ti level in the brain 3 days after a single instillation was upregulated by 100%. | ||
| Wistar rats, male | Intratracheal | Ti accumulation in the brain and dose-dependent injury. TiO2 NPs with diameter of 200 nm did not cause significant alterations in the brain. | ||
| BBB model based on rat primary endothelial cells (BECs) and astrocytes | Acute exposure: 24 h, 0–500 μg/ml | Reduced expression of P-gp, claudin 5, caveolin-1, and caveolin-2 associated with BBB integrity. | ||
| Fisher F344 rats, male | Intravenous | Upregulation of tight junction proteins, modulation of P-gp mRNA expression and persistent brain inflammation markers: IL-1β, IP-10, GFAP and CXCL1. No Ti accumulation in the brain after 24 | ||
| Mice | Intranasal | Ti accumulation in the brain. Oxidative stress, high levels of lipid, protein, and DNA peroxidation, overproliferation of glial cells, tissue necrosis, hippocampal cell apoptosis. Microarray showed significant alterations of 249 genes expression. | ||
| Mice, female | Intranasal instillation | Ti accumulation in hippocampus after 30 days of rutile exposure. | ||
| Mice, female | Intranasal instillation | Imbalance of monoaminergic neurotransmitters, increased NE and 5-HT, while levels of DA, DOPAC, HVA and 5-HIAA were decreased. | ||
| Wistar rats, male | Intragastrical | Downregulated AChE activity. | ||
| Zebrafish embryos | 96 hpf | Hatching time was decreased, with increase in malformation rate. Accumulation in brain with ROS and cell death in hypothalamus. Alterations in behavior and PD-related genes. | ||
| 24 h | GC–MS-based metabolomics perturbations mainly occurred in TCA cycle, glyoxalate, tricarboxylate, inositol phosphate, Gly, Ser, Thr, Gln, and Glu metabolism. | |||
| 96 h under dark or light conditions | Light exposure induced the production of ROS and increased toxicity from a median effect concentration of more than 100 mg/l to 53 mg/l. | |||
| D384 glial cell line and SH-SY5Y human neuroblastoma | 24 h | Concentration- and time-dependent alterations of mitochondrial function, cell membrane damage, inhibition of cell proliferation. Effects dependent on TiO2 size. Neuronal cells were more sensitive than glial cells. | ||
| U373 human glial cells and C6 rat glial cells | 24–96 h | DNA fragmentation assessed in U373 cells, but not in C6 cells. Morphological changes associated with depolymerization of F-actin, apoptotic cell death. | ||
| U373 human glial cells and C6 rat glial cells | 2–24 h | Increased expression of antioxidant enzymes: GPx, CAT, SOD2, lipid peroxidation and mitochondrial depolarization. | ||
| PC12 rat pheochromocytoma | 6–48 h | Apoptosis prevented by a ROS scavenger, N-MPG. | ||
| Co-culture of PC12 cells with primary rat microglia | 24–48 h | Supernatant from TiO2 NPs treated microglia caused significant cytotoxicity in PC12 cells. | ||
| PC12 cell line | 24 h | Decreased cell viability, mitochondrial impairment and decreased DA levels. | ||
| BV2 microgial cells | 6, 18 h | Release of ROS, mitochondrial hyperpolarization | ||
| BV2 microgial cells, N27 neurons, primary cultures of rat striatum | 2, 6, 24, 48 h | Microglia generated ROS damages neurons in complex primary cultures. No cytotoxicity in isolated N27 neurons |
Abbreviations: 5-HIAA: 5-hydroxyindole; 5-HT: 5-hydroxytriptamine; AchE: acetylcholine estarese; BBB: blood-brain barrier; CAT: catalase; CXCL1: chemokine C-X-C motif ligand 1; DA: dopamine; DOPAC: 3,4-dihydrophenylacetic acid; GC–MS: gas chromatography mass spectrometry; GFAP: glial fibrillary acidic protein; Gly: glycine; Gln: glutamine: Glu: glutamate; GPx: glutathione peroxidase; HVA: homovanillic acid; hpf: hours post fertilization; IL-1β: interleukin-1β; IL-6: interleukin-6; IP-10: interferon gamma-induced protein 10; NE: norepinephrine; N-MPG: N-(2-mercaptopropionyl)glycine; NPs: nanoparticles; PD: Parkinson’s disease; P-gp: P-glycoprotein; ROS: reactive oxygen species; Ser: serine; SOD2: superoxide dismutase 2; TCA: tricarboxylic acid cycle; TNF-α: tumor necrosis factor α; Thr: threonine; Ti: titanium; TiO2: titanium dioxide.